pde4 inhibitors
Crisaborole and Apremilast: PDE4 Inhibitors with Similar Mechanism of Action, Different Indications for Management of Inflammatory Skin Conditions
... system, PDE4 isoenzymes are compartmenta- lized in such a manner that inhibition leads to very limited effects on cardiovas- cular parameters such as resting blood pressure, cardiac rate, or myocardial con- ...
25
kNN-MFA-guided 3D-QSAR on Some PDE4 Inhibitors of Benzylamine derivatives For Chronic Obstructive Pulmonary Disease
... k-nearest-neighbour molecular field analysis 3D-QSAR model were S_1789 (-0.0023, -0.0021), E_14 (0.0271, 0.03699). Results showed positive range indicating that positive electrostatic potential is favourable for increase ...
7
EMD273316 & EMD95833, type 4 phosphodiesterase inhibitors, stimulate fibroblastic-colony formation by bone marrow cells via direct inhibition of PDE4 and the induction of endogenous prostaglandin synthesis
... developed PDE4 inhibitors (Merck KGaA, Darmstadt, Germany) having broadly similar activ- ities with respect to PDE4 inhibition whilst being consid- erably less active in terms of PDE3 inhibition ...
10
Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
... oral PDE4 inhibitor roflumilast [3–6], with a lack of effect on symptoms also common [5, 6], while two other inhaled PDE4 inhibitors did not show consistent effects on lung func- tion [24, ...
12
The safety and effectiveness of the current treatment regimen with or without roflumilast in advanced COPD patients: A systematic review and meta-analysis of randomized controlled trials
... oral PDE4 inhibitors (Roflumilast and Cilomilast) in the management of stable COPD, in a re- view of 29 studies which met the inclusion criteria, 15 trials were associated with roflumilast ...
22
PDE4 as a target in preterm labour
... selective inhibitors of some PDEs families are currently used in clinic for treating cardiovascular disorders, erectile dysfunction, and pulmonary ...the PDE4 family are involved in smooth muscle ...
5
Roflumilast: a review of its use in the treatment of COPD
... Roflumilast is generally well tolerated with adverse events (AEs) consistent with those expected for PDE4 inhibitors. Combining the data from several 1-year and 6-month clinical trials of roflumilast (N = ...
10
Targeting phosphodiesterase 4 as a potential therapeutic strategy for enhancing neuroplasticity following ischemic stroke
... of PDE4 is an ideal strategy for the prevention and treatment of peripheral inflammation and immune diseases, such as pulmonary inflammation and psoriasis ...CNS, PDE4 plays a key role in both chronic ...
10
Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
... of PDE4 inhibitors cur- rently available to researchers, most induce side effects of nausea and ...novel PDE4 inhibitor, apremilast has recently been generated [17] which has a half maximal ...
11
Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
... related adverse events was low and similar to those reported previously [9,18]. These treatment-related events included diarrhea, nausea, and headache, which are all adverse events known to be associated with PDE4 ...
10
Phosphodiesterase type 4 expression and anti-proliferative effects in human pulmonary artery smooth muscle cells
... these PDE4 is the main cAMP specific PDE identified in the lung and vascu- lature ...[11,12]. PDE4 proteins are encoded by four genes (PDE4A, PDE4B, PDE4C and PDE4D), which produce numerous PDE4 ...
12
Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors
... Targeting PDE4 has enormous clinical potential due to its mechanism of action, which leads to increased intra- cellular cAMP levels in many different inflammatory cells, decreasing T cell and monocyte-derived ...
13
A multi-target antisense approach against PDE4 and PDE7 reduces smoke-induced lung inflammation in mice
... PDE4B-specific inhibitors might pro- vide better therapeutic ...PDE4B-specific inhibitors might display reduced efficacy as compared to inhibitors targeting both isoforms in the ...develop ...
14
Phosphodiesterase 4-targeted treatments for autoimmune diseases
... of PDE4 inhibitors and the associated literature with a focus on treatments for autoimmune ...selective inhibitors targeting the PDE4 isozyme have been ...of PDE4 inhibitors, ...
8
ajplung.00324.2015.pdf
... and PDE4 inhibitors have previously been shown to stimulate CFTR in human airway epithelial cells, suggesting they could be a therapeutic option for the treatment of ...
12
Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma
... or PDE4 inhibitors within 2 weeks; asthma exacerbation or respiratory tract infection within 4 weeks; previous random assignment in this trial or in the respective twin trial (NCT01172808), or current ...
48
In Silico Designing of Novel Thiazolidine-2-one Derivatives as Dual PDE4/7 Inhibitors for Inflammatory Disorders
... 2007). PDE4 enzyme is mainly expressed in every pro-inflammatory and immunomodulatory cell (Giembycz, 2002; Tasken & Aandahl, ...of PDE4 results in increased levels of intracellular cAMP in inflammatory ...
14
<p>NUT midline carcinoma of the head and neck: current perspectives</p>
... CDK4/6 inhibitors showed synergistic activity with JQ1 on NMC in vitro and in vivo, providing a rationale for combination therapy of BETi and CDK4/6 inhibitors for this ...
10
Progress of small molecular inhibitors in the development of anti-influenza virus agents
... vRNPs inhibitors: As the exportion of influenza virus vRNPs from nuclear has been demonstrated to be mediated by hostexportin 1 (XPO1) (291-293), developing inhibitors of XPO1 to interrupt the vRNP ...
20
SYNTHETIC AND PHARMACOLOGICAL EVALUATION OF SOME 3 (4 {[(SUBSTITUTEDPHENYL) METHYLENE] AMINO} PHENYL) 6 BROMO 2 METHYL QUINAZOLIN 4 ONE DERIVATIVES
... In recent years Quinazoline and quinazolinone derivatives have attracted significant attention due to their diverse pharmacological activities. [1] such as antimalarial. [2] antimicrobial. [3-5] anti-inflammatory. [6-10] ...
8